TGA issued a safety alert on 4 June 2026 after lab testing found undeclared metandienone in Pharmatech MK-677 capsules.
Metandienone is an anabolic steroid with known serious adverse effects; its undisclosed presence poses significant health risks to consumers.
Stop using and dispose of Pharmatech MK-677 capsules immediately; consult a healthcare professional if concerned.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Stop using the capsules immediately. Consult a medical professional if you have concerns. Dispose of any remaining product.
Stop using and dispose of Pharmatech MK-677 capsules immediately; consult a healthcare professional if concerned.
Laboratory testing of Pharmatech MK-677 capsules (containing ibutamoren) revealed undeclared metandienone, an anabolic steroid that can cause liver damage and cardiovascular issues. TGA advises immediate cessation of use and disposal of remaining product.
What changed: TGA issued a safety alert on 4 June 2026 after lab testing found undeclared metandienone in Pharmatech MK-677 capsules.
Why it matters: Metandienone is an anabolic steroid with known serious adverse effects; its undisclosed presence poses significant health risks to consumers.
Practical implication: Stop using and dispose of Pharmatech MK-677 capsules immediately; consult a healthcare professional if concerned.
Published from the Firecrawl agent regulatory extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
